People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Selecta Biosciences Inc | — | Biotechnology | Series D+ | $445.6M | $1.4B | 2011 |
| ADARx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $352.5M | $2.8B | 2020 |
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $494.8M | 2016 |
| Avenzo Therapeutics, Inc. | — | Biotechnology | Series D+ | $270.6M | $355.3M | 2022 |
| ArriVent Biopharma, Inc. | — | Biotechnology | Series D+ | $260.0M | $2.0B | 2022 |
| BlossomHill Therapeutics, Inc. | — | Pharmaceuticals | Series C | $245.8M | $452.2M | 2023 |
| Garuda Therapeutics, Inc. | — | Biotechnology | Series C | $158.0M | $379.8M | 2024 |
| Aragon Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $141.5M | $1.8B | 2009 |
| Kumquat Biosciences Inc | — | Biotechnology | Series C | $135.9M | $815.8M | 2019 |
| Compass Therapeutics LLC | — | Biotechnology | Series D+ | $132.6M | $900.7M | 2015 |
| Star Therapeutics LLC | — | Pharma | Series D+ | $125.0M | $935.3M | 2025 |
| Adicet Bio, Inc. | — | Biotechnology | Series C | $116.8M | $3.3B | 2015 |
| Scribe Therapeutics, Inc. | — | Pharma | Series D+ | $100.0M | $2.9B | 2021 |
| Keros Therapeutics, Inc. | — | Biotechnology | Series C | $78.5M | $2.3B | 2020 |
| Igenica Inc | — | Pharmaceuticals | Series B | $70.0M | $76.5M | 2010 |
| Intellia Therapeutics, Inc. | — | Biotechnology | Series C | $70.0M | $2.9B | 2015 |
| Prevail Therapeutics Inc. | — | Pharma | Series C | $57.0M | $2.0B | 2018 |
| Lomond Therapeutics Holdings, Inc. | — | Pharmaceuticals | Series C | $53.9M | $419.4M | 2024 |
| Singulex Inc | — | Biotechnology | Series B | $44.7M | $483.8M | 2011 |
| Alector LLC | — | Biotechnology | Series B | $32.3M | $1.3B | 2015 |
| Good Start Genetics, Inc. | — | Biotechnology | Series B | $28.2M | $396.9M | 2012 |
| SpringWorks Therapeutics, LLC | — | Pharma | Series A | $12.8M | $396.9M | 2017 |
| Gemini Therapeutics, Inc. | — | Biotechnology | Seed | $2.0M | $88.8M | 2016 |
| Amnis Corp | — | Biotechnology | Pre-Seed | $894K | $49.3M | 2009 |
Carl Gordon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carl Gordon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| CARL L. GORDON | 3 | 7 |
| Stephen Squinto | 2 | 8 |
| Judith Li | 2 | 8 |
| Simeon George | 2 | 8 |
| Erez Chimovits | 2 | 7 |
| Tillman Gerngross | 2 | 5 |
| Hongbo Lu | 2 | 4 |
| Adam Craig | 2 | 2 |
| David Kirske | 2 | 2 |
| CARL J. GORDON | 2 | 2 |
| Michael Ross | 1 | 18 |
| Asish Xavier | 1 | 18 |
| Jean-Francois Formela | 1 | 17 |
| Peter Thompson | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Peter Barton Hutt | 1 | 14 |
| BIHUA CHEN | 1 | 14 |
| David Perry | 1 | 11 |
| Annette Campbell-White | 1 | 11 |
| Amy Schulman | 1 | 11 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.